Overview

* Viridian Q2 revenue of $75,000 beats analyst expectations

* Cash position at $563.4 mln supports operations into 2H 2027

Outlook

* Viridian says Biologics License Application (BLA) submission for veligrotug on track in 2H 2025

* Company expects veligrotug U.S. commercial launch in 2026

* Viridian anticipates VRDN-003 topline data in 1H 2026

* Company plans VRDN-008 IND submission on track for year-end 2025

Result Drivers

* LICENSING AGREEMENT - Viridian secured a $70 mln upfront payment from Kissei for Japan licensing deal, with potential milestones up to $315 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $75,000 $43,600

Revenue (14

Analysts

)

Q2 Net -$100.74

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Viridian Therapeutics Inc ( VRDN ) is $38.00, about 54.1% above its August 5 closing price of $17.44

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)